Avid Bioservices Inc (CDMO)

[pphmtoolong]

Given the huge Sunrise disappointment, Peregrine is forging ahead in an efficient way on the Avid and Bavituximab fronts.

As usual they ran into image damaging bad luck from the third party contractor reviewing the Avid output. This time the damage should make the next quarter look good.

There is still reason to be hopeful the share price will improve, if it can handle the inevitable reverse split without too much trouble. Remains to be seen.

GLTA, Paul